degeneration is believed to be a multifactorial process involving genetic predisposition, inflammatory mediators, oxidative stress, and hypoxia-induced angiogenesis. Although the interplay of these factors remains elusive, increasing evidence points toward an underlying ischemic process as a major contributing factor to agerelated macular degeneration (AMD) pathogenesis. Abnormalities of the choroidal circulation are associated with the development of choroidal neovascularization (CNV) in patients with AMD by a process that may involve ischemia, hypoxia, and resultant vascular endothelial growth factor (VEGF) production.
T HE PATHOGENESIS OF AGE-RELATED MACULAR
degeneration is believed to be a multifactorial process involving genetic predisposition, inflammatory mediators, oxidative stress, and hypoxia-induced angiogenesis. Although the interplay of these factors remains elusive, increasing evidence points toward an underlying ischemic process as a major contributing factor to agerelated macular degeneration (AMD) pathogenesis. Abnormalities of the choroidal circulation are associated with the development of choroidal neovascularization (CNV) in patients with AMD by a process that may involve ischemia, hypoxia, and resultant vascular endothelial growth factor (VEGF) production. [1] [2] [3] [4] [5] [6] [7] [8] [9] Choroidal circulation abnormalities, as displayed by fluorescein and indocyanine green angiography, [10] [11] [12] color Doppler flowmetry, [13] [14] [15] [16] laser Doppler flowmetry, 1, 17 pulsatile ocular blood flow, 2, 18 and histopathologic analyses, 19, 20 have been associated with progression of AMD. The choroidal circulation plays a vital role in both the provision of oxygen and nutrients to the outer retina, as well as removal of metabolic waste products. Impairment of these functions may contribute to accumulation of Bruch's membrane deposits, retinal atrophy, and CNV.
The results from several previous studies suggested a role for decreased choroidal blood flow in the development of CNV in AMD. 21 Decreased choroidal blood flow is associated with many AMD risk factors, including extent of drusen, retinal hyperpigmentary changes, hypertension, and hyperopia. 22, 23 Furthermore, in a longitudinal study of choroidal blood flow in AMD patients, Metelitsina and associates reported that patients who demonstrated CNV during the study had lower choroidal blood flow at baseline than those who did not demonstrate CNV. 24 In addition, choroidal blood flow decreased before CNV formation, suggesting a role for ischemia in the development of CNV. Finally, patients with lower choroidal blood flow at baseline were 3 times more likely to experience decreases in visual acuity during the study.
A different line of evidence pointing to a role of decreased choroidal blood flow and ischemia in the pathogenesis of CNV can be derived from reports suggesting that in exudative AMD patients, there is a tendency for CNV to form in proximity to angiographically documented watershed areas 3, 4, 10 where blood flow may be diminished. In addition, Stefánsson and associates recently noted features of AMD that may contribute to abnormal retinal oxygen metabolism and potentially ischemia, including the presence of confluent drusen, retinal elevation, retinal edema, and vitreoretinal adhesion. 9 Delayed filling of the choroidal lobules during the transit phase of fluorescein angiography, or delayed patchy choroidal filling, may be related to decreased choroidal circulation, as seen in choroidal ischemia secondary to vascular diseases. 11, 25, 26 In this study, we investigated the association of delayed patchy choroidal filling with morphologic and functional outcomes after anti-VEGF treatment in participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
METHODS

INSTITUTIONAL REVIEW BOARD APPROVAL WAS OBTAINED
from the University of Pennsylvania and all participating CATT clinical centers. Each participant provided written informed consent that complied with the Health Insurance Portability and Accountability Act before entry into the study. Details regarding the methodology of the CATT study, an interventional double-masked trial, have been reported previously and also can be reviewed at ClinicalTrials. gov (identifier, NCT00593450). 27 Below is a description of the methodology involved in this cohort study within the CATT pertaining to the fluorescein angiography evaluation of choroidal filling in study participants.
STUDY PARTICIPANTS: A total of 1185 participants from 43 clinical centers in the United States were enrolled in the CATT between 2008 and 2009. After written consent was obtained, study participants were randomized to 1 of the 4 treatment groups: (1) ranibizumab monthly, (2) bevacizumab monthly, (3) ranibizumab pro re nata (PRN), and (4) bevacizumab PRN. Inclusion criteria for the study included the presence of active CNV, subfoveal involvement by CNV or sequelae of CNV, fibrosis of less than 50% of total lesion area, visual acuity of 20/25 to 20/320, age of 50 years or older, and at least 1 drusen (>63 mm) in either eye or late AMD in the fellow eye. Exclusion criteria included previous treatment for CNV in the study eye, other progressive retinal disease likely to compromise visual acuity, as well as any contraindications to injections with ranibizumab or bevacizumab.
STUDY PROCEDURES: During the initial visit to the participating centers, several baseline characteristics were recorded including age, gender, race, smoking status, systolic and diastolic blood pressures, and use of antihypertensive medications. Visual acuity was measured in both eyes after refraction using the Electronic Visual Acuity Tester following the protocol used in the Diabetic Retinopathy Clinical Research Network. 28 Systemic hypertension was defined as a systolic blood pressure of 160 mm Hg, diastolic blood pressure of 95 mm Hg, or current use of antihypertensive medications.
Trained photographers followed a standard protocol to obtain color fundus photographs and fluorescein angiograms before initiation of anti-VEGF therapy and at 1 year of follow-up. All photographs were digital with the exception of 1 site that carried out film-based imaging.
Graders at the CATT fundus photograph reading center reviewed color photographs and fluorescein angiograms of study eyes (1 study eye per subject) and recorded the presence or absence of CNV, CNV lesion type (ie, predominantly classic, minimally classic, occult only, and cannot grade or no lesion), and retinal angiomatous proliferation. The total CNV lesion area was measured at baseline by taking into consideration the area of CNV plus any associated hemorrhage, scarring, blocked fluorescence, or pigment epithelial detachment associated with neovascularization. At follow-up, areas of geographic atrophy in areas previously occupied by the CNV lesion were included in the measurement to the total CNV lesion area. Graders at the CATT optical coherence tomography (OCT) reading center reviewed time-domain OCT images and recorded the presence of intraretinal fluid, subretinal fluid, or subretinal pigment epithelial fluid. Total retinal thickness in micrometers was measured at the foveal center based on the average of 6 fast macular OCT scans.
For the evaluation of the choroidal filling pattern, 2 trained readers (D.Y.G., C.P.O.) in the CATT photograph reading center initially determined whether delayed patchy choroidal filling was present at baseline and 1 year after anti-VEGF treatment. Nonphysiologic delayed patchy choroidal filling was deemed present if at least half a disc diameter of patchy choroidal filling was present beyond the early venous transit phase. The early venous transit phase was defined as lamellar filling with fluorescein that comprised less than half of the diameter of the larger retinal venules. At least 2 clear transit frames were required to evaluate a series. In equivocal cases, a third senior grader (J.E.G.) adjudicated. Photographs from the first 5% of patients were graded by both trained readers to assess intergrader agreement with respect to presence of delayed patchy choroidal filling (yes/no/can't grade; n ¼ 118 photographs; 94.1% agreement; k, 0.89; 95% confidence interval [CI], 0.82 to 0.97), and subsequent to the determination of acceptable agreement, all patient photographs were assigned randomly to only 1 grader. Only the 1118 eyes that had undergone angiography at both baseline and 1 year were graded for delayed patchy choroidal filling. All assessments were performed without access to demographic data, treatment allocation, and clinical outcomes.
DATA ANALYSIS:
The comparisons between groups of eyes based on presence of delayed patchy choroidal filling were performed for baseline characteristics and morphologic and functional outcomes at 1 year using the Fisher exact test for proportions and the independent t test for means. Similar comparisons were made between groups of eyes based on development of delayed patchy choroidal filling within 1 year. The McNemar test was used for comparisons of delayed patchy choroidal filling in the same eyes over time. All data analyses were performed using Statistical Analysis Software version 9.3 (SAS, Inc, Cary, North Carolina, USA).
RESULTS
BASELINE CHARACTERISTICS OF STUDY PARTICI-PANTS:
Among the 1118 graded eyes, 973 (87.0%) were gradable for delayed patchy choroidal filling, and 75 (7.7%) of these had evidence of delayed patchy choroidal filling at baseline. Figure shows a typical case of delayed patchy choroidal filling.
The mean age was 79.3 years in patients with baseline delayed patchy choroidal filling and 78.8 years in patients with normal baseline choroidal filling; this difference was not statistically significant (difference [D], 0.5; 95% CI, À1.3 to 2.2; P ¼ .62; Table 1 ). The mean baseline visual acuity was 62.1 letters in those with baseline delayed patchy choroidal filling and 61.3 letters in those without baseline delayed patchy choroidal filling; this difference was not significant (D, 0.8; 95% CI, À1.3 to 2.2; P ¼ .61). There were no statistically significant differences in gender, race, smoking status, hypertension, CNV area, CNV lesion type, or retinal angiomatous proliferation lesion type and OCT total retinal thickness between patients with and those without baseline delayed patchy choroidal filling.
When we compared the 1-year outcomes between eyes without delayed patchy choroidal filling at baseline and eyes with delayed patchy choroidal filling at baseline, we also found no statistically significant differences in visual acuity, total area of CNV lesion, presence of fluorescein leakage, total OCT retinal thickness, presence of OCT fluid, presence of scar, and geographic atrophy ( Table 2) .
Among the 75 eyes with delayed patchy choroidal filling at baseline, delayed patchy choroidal filling was observed after the early venous phase in 8 eyes (11%), after the late venous phase in 56 eyes (75%), and past the transit phase entirely in 11 eyes (15%). There was no significant difference in visual acuity between these eyes with different degrees of delayed patchy choroidal filling (P ¼ .23, data not shown).
CHANGES IN OCULAR CHARACTERISTICS COMPARED
WITH BASELINE: Among the 973 eyes gradable at baseline, 860 (88.4%) were gradable for delayed patchy choroidal filling at 1 year. Participants were divided into 4 descriptive groups based on the delayed patchy choroidal filling status at baseline and at 1 year: no delayed patchy choroidal filling at baseline or at 1 year (n ¼ 775; 90.1%); delayed patchy choroidal filling present at baseline and 1 year (n ¼ 51; 5.9%); no delayed patchy choroidal filling at baseline, but development of delayed patchy choroidal filling at 1 year (incident cases at 1 year, n ¼ 23; 2.7%); and delayed patchy choroidal filling present at baseline, but not at 1 year (disappeared cases, n ¼ 11; 1.3%). The patchy status comparison at baseline and at 1 year indicates that there were significantly more incident cases than disappeared cases (P ¼ .04). The mean change in visual acuity over 1 year was À1.7 letters (95% CI, À8.7 to 5.2 letters) in those with incident delayed patchy choroidal filling and þ8.1 letters (95% CI, 7.1 to 9.1 letters) in patients with normal choroidal filling at both baseline and 1 year; this difference was statistically significant (D, À9.8; 95% CI, À15.8 to À3.9; P < .01; Table 3 ). Incident delayed patchy choroidal filling cases at 1 year also displayed a larger increase in mean total CNV lesion area (D, 2.4; 95% CI, 0.4 to 4.4; P ¼ .02) and a smaller but not significant decrease in OCT total retinal thickness (D, 44.2; 95% CI, À28.1 to 116.5; P ¼ .23).
At 1 year, there were no statistically significant differences in fluorescein leakage; presence of intraretinal fluid, subretinal fluid, or subretinal pigment epithelium fluid; or development of scar or geographic atrophy between the eyes in which delayed patchy choroidal filling developed at 1 year and the eyes that did not have delayed patchy choroidal filling at baseline and 1 year. Among the 23 incident delayed patchy choroidal filling eyes at 1 year, delayed patchy choroidal filling was observed only through the early venous phase in 4 eyes (17%), through late venous in 14 eyes (61%), and past the transit phase entirely in 5 eyes (22%). There was no significant difference in visual acuity between these eyes with varying degrees of delayed patchy choroidal filling (P ¼ .36, data not shown).
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AND DELAYED PATCHY CHOROIDAL FILLING:
The incidence of delayed patchy choroidal filling was similar in eyes treated with ranibizumab (10/413; 
DISCUSSION
THE PRESENCE OF DELAYED PATCHY CHOROIDAL FILLING was a relatively rare finding, observed at baseline in less than 8% of participants. In comparison with baseline, there was a small, but statistically significant, increase in delayed patchy choroidal filling after 1 year of treatment, suggesting a more delayed choroidal filling time at 1 year. Whether this is an effect of the anti-VEGF treatment or an effect of aging, which is known to be associated with decreased choroidal blood flow, 29 cannot be answered in our study because of the lack of a control group. There were 11 patients (1.3%) who had delayed patchy choroidal filling at baseline but did not have it at 1 year. This may be the result of fluctuations in choroidal filling that may be related to blood pressure changes and heart rate changes or other physiologic parameters that may influence choroidal blood flow. In addition, this phenomenon may be the result of variations in the determination of delayed patchy choroidal filling.
We found no statistically significant differences in vision and anatomic outcomes at baseline between eyes with and eyes without delayed patchy choroidal filling at baseline. Eyes in which delayed patchy choroidal filling developed after 1 year in the study, however, had significantly worse visual acuity and larger increases in total CNV lesion area than those in which this feature did not develop during the study.
Evidence of retinal vasoconstriction after ranibizumab therapy has been reported by Papadopoulou and associates in a study performed in 11 AMD eyes that received monthly intravitreal injections of ranibizumab for 3 consecutive months. 30 This study showed significant vasoconstriction of retinal arterioles ranging from 8.1 6 3.2% at 30 days after the first injection to 11.5 6 4.4% at 30 days after the second injection and 17.6 6 7.4% at 30 days after the third injection. An additional preliminary report by Fontaine and associates also suggests the presence of arteriolar vasoconstriction of approximately 5% after bevacizumab treatment in 16 patients with neovascular AMD. 31 Although there are no reports on the effect of anti-VEGF therapy on the choroidal vessel diameter, it is possible that the vasoconstriction reported in the retina also may occur in the choroidal vasculature. A recent report of Yamazaki and associates showing significant decreases in subfoveal choroidal thickness measured by OCT after anti-VEGF intravitreal injections supports this hypothesis. 32 Vasoconstriction of both retinal and choroidal vessels could result in a decreased perfusion of the macula with deleterious consequences. Although there is evidence that anti-VEGF drugs cause vasoconstriction, reduction of choroidal blood flow as determined by incident delayed patchy choroidal filling was rare in this study, with a rate of 2.7% (23 patients). 30, 31 Our results showing worse visual acuity and larger increases in total CNV lesion area in eyes with incident delayed patchy choroidal filling at 1 year suggest that a decreased macular circulation may have a role in the lack of improvement in visual acuity after anti-VEGF therapy in some patients.
We found no significant differences in the incidence of delayed patchy choroidal filling between ranibizumab or bevacizumab treatment (D, 1.0%; 95% CI, À1.1% to 3.3%; P ¼ .53) and between the monthly and PRN treatment schedules (D, 0.4%; 95% CI, À1.9% to 2.7%; P ¼ .83). Our number of cases with incident patchy delayed choroidal filling is rather small, and a larger population may be needed to reach any strong conclusions regarding this point.
Our study did not reveal a statistically significant association between baseline delayed patchy choroidal filling and systemic hypertension or smoking status. However, there was a marginally significant difference in smoking (P ¼ .09), with a higher percent of current smoking in the delayed patchy choroidal filling group (16.0% vs 8.8%; Table 1 ). The small number of cases with delayed patchy choroidal filling may not allow us to make any strong conclusions regarding this point. Additionally, it is possible that antihypertensive treatment may affect the relationship between delayed patchy choroidal filling and blood pressure.
In summary, our results suggest that the presence of delayed patchy choroidal filling is rare at baseline, being present in less than 8% of participants (75 patients). Interestingly, the 23 (2.9%) incident cases of delayed patchy choroidal filling at 1 year displayed worse visual acuity and larger increases in total CNV lesion area, suggesting that decreased perfusion could have a role in explaining poor visual outcomes in patients treated with anti-VEGF therapy. VOL. 158, NO. 3 531.e2 CHOROIDAL FILLING AND AGE-RELATED MACULAR DEGENERATION
